Alpharma Showcasing U.S. Pharmaceutical Division at AAPS Meeting
Alpharma's USPD is the market leader in generic liquid and topical pharmaceuticals in the United States, with an expanding position in other specialty products. Marketing the broadest portfolio of manufactured products in its industry with over 170 products in both prescription (Rx) and over-the-counter (OTC) categories. USPD is the only major generic drug company with a substantial presence in consumer pharmaceuticals. With approximately 60 OTC products, USPD is becoming an increasingly important partner to major retailers and is well positioned to compete for the Rx to OTC switch products.
As the generic drug industry has grown, the largest wholesalers have moved to limit their suppliers to companies capable of supplying broad product lines on a national basis, such as USPD. To further capitalize on the opportunities for growth present in this rapidly changing and consolidating industry, USPD is forming new partnership alliances. USPD recently completed new licensing agreements with Xactdose, a unit-dose manufacturer and Penederm Inc., which specializes in dermatological products utilizing the patented TopiCare Delivery Compound technology.
At USPD, new marketing strategies and customer-oriented initiatives were established during 1997 to meet the changing needs of the marketplace, including new packaging designs to establish brand identity. Category management, building products around therapeutic categories such as cough and cold, women's health and pediatric care for example, is critical to success and allows USPD customers to offer consumers a unified line of generically-priced products. As part of USPD's customer-oriented marketing approach, they have developed new dedicated customer service and quality assurance teams.
Building upon its expertise in developing, manufacturing and distributing multi-source liquids, semi-solids and specialty pharmaceutical products, USPD's current research and development objectives include: establishing new product development as a cross-functional activity and reducing development-to-approval time; providing a consistent flow of first-to-market products and enhancing product effectiveness through advanced delivery systems; leveraging scientific and regulatory expertise to accelerate new product introductions, and using automation and information system networks to enhance effectiveness, productivity and precision in creating high quality submissions.
For more information: Thomas Anderson, President, Alpharma USPD, 7205 Windsor Blvd., Baltimore, MD 21244. Tel: 410-298-1000. Fax: 410-298-6343.